UB-421
Sponsors
United BioPharma, UBP Greater China (Shanghai) Co., Ltd, National Institute of Allergy and Infectious Diseases (NIAID)
Conditions
HIV-1 InfectionHIV-1-infectionMulti-Drug Resistant Hiv-1 Infection
Phase 2
To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults
CompletedNCT02369146
Start: 2015-06-30End: 2016-07-31Updated: 2017-10-31
UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients
NCT03164447
Start: 2023-12-31End: 2024-05-31Target: 10Updated: 2023-04-24
the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients
WithdrawnNCT04041362
Start: 2020-04-30End: 2021-03-31Updated: 2020-02-21
A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir
Not yet recruitingNCT04985890
Start: 2024-03-31End: 2027-12-31Target: 20Updated: 2023-05-10
A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs
CompletedNCT05056974
Start: 2021-12-02End: 2023-02-01Updated: 2023-02-15
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection
WithdrawnNCT05582694
Start: 2025-07-10End: 2025-07-10Updated: 2025-07-11
Phase 3
To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults
WithdrawnNCT03149211
Start: 2025-04-01End: 2025-12-31Updated: 2023-04-25
UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection
Not yet recruitingNCT04406727
Start: 2023-12-01End: 2026-06-30Target: 50Updated: 2023-04-24